Adaptive Biotechnologies' stock was trading at $28.06 at the beginning of the year. Since then, ADPT shares have decreased by 66.6% and is now trading at $9.3650. View the best growth stocks for 2022 here.
Full Answer
What does adaptive phage Therapeutics do?
GAITHERSBURG, Md., (BUSINESS WIRE) -- Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the AMR Action Fund has joined an existing $41 million Series B round as a co-investor.
What is apt phagebank?
APT PhageBank uniquely adapts in spectrum of coverage to overcome emerging bacterial resistance. Our approach addresses today’s – and tomorrow’s – toughest infections. The useful lifespan of new antibiotics has suffered due to the emergence of bacterial resistance.
When is adaptive Biotechnologies'next quarterly earnings announcement?
Adaptive Biotechnologies is scheduled to release its next quarterly earnings announcement on Wednesday, May 4th 2022. View our earnings forecast for Adaptive Biotechnologies. How were Adaptive Biotechnologies' earnings last quarter? Adaptive Biotechnologies Co. (NASDAQ:ADPT) announced its quarterly earnings data on Tuesday, February, 15th.
When is adaptive Biotechnologies’ management presentation?
Adaptive Biotechnologies’ management is scheduled to present on Monday, January 10th at 10:30 a.m. Pacific Tim Read more to see why three Fool.com contributors think COVID stocks Fulgent Genetics (NASDAQ: FLGT), NRx Pharmaceuticals (NASDAQ: NRXP), and Adaptive Biotechnologies (NASDAQ: ADPT) could double your money this year.
Adaptive Phage Therapeutics Comparisons
Provider of therapeutic services intended to treat multi-drug resistant pathogenic bacteria. The company's services are
Adaptive Phage Therapeutics Signals
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
What is adaptive biotechnology?
Pacific Time / 9:40 a.m. Eastern Time Goldman Sachs 42nd Annual Global Healthcare ConferenceFireside Chat on Tuesday, June 8th at 12:50 p.m. Pacific Time / 3:50 p.m. Eastern Time Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com. About Adaptive BiotechnologiesAdaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. ADAPTIVE INVESTORSKarina Calzadilla, Vice President, Investor Relations201-396-1687Carrie Mendivil, Gilmartin [email protected] ADAPTIVE MEDIABeth [email protected]
What is adaptive immunoseq?
Adaptive’s immunoSEQ T-MAP COVID provides potential explanation for preservation of Johnson & Johnson vaccine (Ad26.COV2.S) response to variants even when neutralizing antibodies are diminishedSEATTLE, June 09, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that immunoSEQ® T-MAP™ COVID was u
When will Axsome 14 be released?
The company will file an NDA in the fourth quarter of 2022.
Antimicrobial Resistance (AMR) is a world-wide crisis caused by ongoing evolution of bacteria
APT PhageBank uniquely adapts in spectrum of coverage to overcome emerging bacterial resistance. Our approach addresses today’s – and tomorrow’s – toughest infections.
Precise superbug therapy
Adaptive Phage Therapeutics (APT) is a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria.
Success Story
In 2016 APT’s approach achieved its first in-human success with the rescue of a critically ill MDR infected patient: Tom Patterson, multi-drug resistant Acinetobacter baumannii survivor.
APT in the news
Adaptive Phage Therapeutics (APT), announced the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for the treatment of prosthetic joint infections (PJI) utilizing PhageBank™. Orphan drug designation is given […]
About Adaptive Biotechnologies
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines.
Adaptive Biotechnologies (NASDAQ:ADPT) Frequently Asked Questions
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock.